Why patients respond to a life-saving melanoma drug

Wednesday, November 26, 2014 - 15:30 in Health & Medicine

Researchers have pioneered a new methodology to predict why some patients battling advanced melanoma respond well or not at all to the new breakthrough drug pembrolizumab (Keytruda).

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net